Physician profile
James Stanek
NPI 1720581762
$946.17
in general payments reported to CMS, 2019-2025
9 companies · $34.99 in 2025
The $34.99 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $72.09 · 2022: $109 · 2023: $515 · 2024: $215 · 2025: $34.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $304.90 | 2022-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $134.96 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $116.66 | 2023-2024 | Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $90.01 | 2023-2024 | Rexulti, Abilify Maintena |
| Corium, LLC | $74.14 | 2023 | Azstarys |
| Alkermes, INC. | $67.26 | 2022-2023 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $57.35 | 2022-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $52.31 | 2023 | Spravato |
| Axsome Therapeutics, INC. | $48.58 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Stanek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.